Publicaciones científicas sobre los diagnósticos no invasivos de BioPredictive
Estudios revisados por pares que validan los diagnósticos por análisis de sangre de BioPredictive para enfermedades hepáticas — desde cohortes de desarrollo pioneras hasta metaanálisis a largo plazo.
138/435
Coincidencias para
“randomized trial”
-
A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis.
…12-month, randomized, double-blind, placebo-controlled multicenter trial to evaluate the…
-
Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action. Review
Traditionally a disease of hepatologists, nonalcoholic fatty liver disease (NAFLD) has recently…
-
Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin.
…using the data of a randomized trial of combination peginterferon alfa-2b…
-
Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial. Key publication
…in patients included in a randomized trial of interferon (IFN) using repeated…
-
EASL clinical practical guidelines: management of alcoholic liver disease.
-
EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease.
-
Impact of effective versus sham continuous positive airway pressure on liver injury in obstructive sleep apnoea: Data from randomized trials.
…NashTest and FibroTest) through three randomized sham controlled studies. ### Methods The FibroMax…
-
Non-invasive assessment of liver fibrosis progression in hepatitis C patients retreated for 96 weeks with antiviral therapy: a randomized study.
…fibrosis score > or = 2 were randomized to receive peginterferon alpha-2a 180…
-
Non-invasive diagnosis of large oesophageal varices with FibroTest in patients with cirrhosis: a preliminary retrospective study.
### Background And Aims Primary prevention of variceal bleeding with beta-blockers improves…
-
Hepatoprotective Effect of Antrodia cinnamomea Mycelium in Patients with Nonalcoholic Steatohepatitis: A Randomized, Double-Blind, Placebo-Controlled Trial.
…NASH in this 6-month randomized, double-blind, placebo-controlled study. ### Method…
-
Improved inflammatory activity with peginterferon alfa-2b maintenance therapy in non-cirrhotic prior non-responders: a randomized study.
…EPIC(3) included a prospective trial assessing long-term peginterferon alfa-2b…
-
FibroTest-FibroSURE: towards a universal biomarker of liver fibrosis?
Among the noninvasive alternatives to liver biopsy, several studies have demonstrated the…
-
Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C.
SUMMARY: BACKGROUND: Recent studies strongly suggest that due to the limitations and…
-
Impact of adefovir dipivoxil on liver fibrosis and activity assessed with biochemical markers (FibroTest-ActiTest) in patients infected by hepatitis B virus. Key publication
…Patients with chronic hepatitis B (HBeAg+ and HBeAg-) randomized in two trials…
-
Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Key publication
-
Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity.
…1980 to 2010 searching for randomized controlled trials and observational studies on…
-
Noninvasive prediction of fibrosis in patients with chronic hepatitis C.
-
Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stages. Key publication
### Background The area under the ROC curve (AUC) is widely used as…
-
EASL Clinical Practice Guidelines: management of hepatitis C virus infection.
-
The predictive value of Fibrotest vs. APRI for the diagnosis of fibrosis in chronic hepatitis C.
-
Appropriate evidence-based data overviews demonstrate the diagnostic and prognostic performances of FibroTest in patients with chronic hepatitis C.
-
Meta-analyses of FibroTest diagnostic value in chronic liver disease. Key publication Meta Analysis
### Background FibroTest (FT) is a biomarker of liver fibrosis initially validated in…
-
Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease?
### Background Few data are available on chronic hepatitis C (CHC) in elderly…
-
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.
-
FibroSURE and FibroScan in relation to treatment response in chronic hepatitis C virus.
…Patients with chronic HCV were randomized to receive interferon-based therapy for…
-
Liver fibrosis: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL). Key publication
Liver fibrosis is a common pathway leading to cirrhosis, which is the…
-
Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection
These are the first World Health Organization (WHO) guidelines for the prevention…
-
Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest).
### Background FibroTest and elastography have been validated as biomarkers of liver fibrosis…
-
Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups.
### Background Our aim was to assess the natural history of liver fibrosis…
-
Biomarkers of liver fibrosis. Review
Liver biopsy, due to its limitations and risks, is an imperfect gold…
-
Biomarkers of liver injury for hepatitis clinical trials: a meta-analysis of longitudinal studies. Meta Analysis
### Background Liver biopsy and virological end points are standard references for assessing…
-
ActiTest accuracy for the assessment of histological activity grades in patients with chronic hepatitis C, an overview using Obuchowski measure. Meta Analysis
### Background ActiTest (AT) is a biomarker of liver necro-inflammatory histological activity…
-
FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest.
### Unlabelled To optimize the management of patients with chronic hepatitis C virus…
-
A prospective assessment of an 'a la carte' regimen of PEG-interferon alpha2b and ribavirin combination in patients with chronic hepatitis C using biochemical markers.
In therapy with standard interferon and ribavirin, five independent risk factors (RF…
-
An independent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE and FIBROSpect II) during albinterferon alfa-2b combination therapy for chronic hepatitis C.
Noninvasive markers that accurately follow changes in fibrosis may provide alternatives to…
-
Non-cirrhotic thrombocytopenic patients with hepatitis C virus: Characteristics and outcome of antiviral therapy.
### Background And Aim Thrombocytopenia is frequently observed in patients with chronic hepatitis…
-
FibroTest-ActiTest as a non-invasive marker of liver fibrosis. Key publication Meta Analysis
FibroTest (FT) is a biomarker of liver fibrosis initially validated in patients…
-
EASL clinical practice guidelines: Management of chronic hepatitis B virus infection.
-
An Invisible Early Steatosis Phenotype Defined for a Large Population-Based Cohort.
**Background:** The current definition of metabolic dysfunction-associated steatotic liver disease (MASLD…
-
Impact of hepatitis C and liver fibrosis on antiretroviral plasma drug concentrations in HIV-HCV co-infected patients: the HEPADOSE study.
### Objectives To compare plasma antiretroviral concentrations in HIV-HCV co-infected and…
-
Longitudinal assessment of histology surrogate markers (FibroTest-ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection.
### Objectives The noninvasive serum markers, FibroTest-ActiTest (FT-AT), are an alternative…
-
An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver. Key publication
Chronic hepatitis C remains a significant medical and economic burden in Canada…
-
Nonalcoholic fatty liver disease, nocturnal hypoxia, and endothelial function in patients with sleep apnea.
### Background Nocturnal hypoxia, the hallmark of OSA, is a potential contributing factor…
-
Correlation between liver biopsy and fibrotest in the evaluation of hepatic fibrosis in patients with chronic hepatitis C.
### Aim To assess the diagnostic value of Fibrotest in comparison with liver…
-
Silymarin in non alcoholic fatty liver disease.
### Aim This study was undertaken to evaluate the hepatic effects of silybum…
-
Assessment of methotrexate hepatotoxicity in psoriasis patients: a prospective evaluation of four serum fibrosis markers.
### Background Low-dose oral methotrexate (MTX) is an effective immunosuppressive therapy for…
-
FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC³ program.
### Background & Aims EPIC-3 is a prospective, international study that has demonstrated…
-
Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients.
### Unlabelled Nonalcoholic fatty liver disease (NAFLD) is highly prevalent and being overweight…
-
Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors.
Combinations of tests comprising alpha2-macroglobulin, haptoglobin, apolipoprotein Al, gamma-glutamyltransferase, total…
-
Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C.
### Background & Aims Chronic hepatitis C is both a virologic and fibrotic disease…
-
Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B.
### Background Aims Liver biopsy is the gold standard for assessing hepatitis B…
-
The new paradigm of hepatitis C therapy: integration of oral therapies into best practices. Review
Emerging data indicate that all-oral antiviral treatments for chronic hepatitis C…
-
Non-alcoholic fatty liver disease biomarkers estimate cardiovascular risk based on coronary artery calcium score in type 2 diabetes: a cross-sectional study with two independent cohorts. Key publication
…coronary calcification and cardiovascular risk. ### Trial Registration ClinicalTrials.gov identifiers NCT02431234 and…
-
Value of two noninvasive methods to detect progression of fibrosis among HCV carriers with normal aminotransferases.
The course of hepatitis C virus (HCV) infection carriers with normal/near…
-
Changes of non-invasive markers and FibroScan values during HCV treatment.
The recent advent of non-invasive methods for assessment of fibrosis allows…
-
Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease.
### Background & Aims The aim of this study was to determine the diagnostic…
-
Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest™) and transient elastography (FibroScan®).
### Background & Aims FibroTest™ (FT) and Transient Elastography (TE) have been validated as…
-
The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Key publication
### Background Biopsy is the usual gold standard for liver steatosis assessment. The…
-
Intra-individual fasting versus postprandial variation of biochemical markers of liver fibrosis (FibroTest) and activity (ActiTest).
BACKGROUND: Biochemical marker combinations, including alpha2-macroglobulin, haptoglobin, apolipoprotein A1, gamma-glutamyl…
-
Biological markers of liver fibrosis and activity as non-invasive alternatives to liver biopsy in patients with chronic hepatitis C and associated mixed cryoglobulinemia vasculitis.
### Objective And Methods We assessed the reliability of non-invasive biological scoring…
-
Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experience. Key publication Review
-
Noninvasive Markers of Improvement of Liver Steatosis Achieved by Weight Reduction in Patients with Nonalcoholic Fatty Liver Disease.
### Unlabelled Nonalcoholic fatty liver disease (NAFLD) is strongly associated with insulin resistance…
-
Guidelines for the Screening, Care and Treatment of Persons with Hepatitis C Infection Key publication
These are the first guidelines dealing with hepatitis C treatment produced by…
-
Assessment of liver fibrosis with transient elastography and FibroTest in patients treated with methotrexate for chronic inflammatory diseases: a case-control study.
### Background & Aims Although methotrexate (MTX) is used in the effective treatment of…
-
The FibroTest value in discriminating between insignificant and significant fibrosis in chronic hepatitis C patients. The Romanian experience.
### Aim To assess the diagnostic value of FibroTest to discriminate between insignificant…
-
Diagnostic value of FibroTest with normal serum aminotransferases.
-
Comparison of FibroTest-ActiTest with histopathology in demonstrating fibrosis and necroinflammatory activity in chronic hepatitis B and C.
### Aims FibroTest and ActiTest are noninvasive tests used in determining the level…
-
[Prognosis assessment of alcoholic liver disease: how and why?]. Review
Alcoholic liver disease (ALD) causes more than 5000 deaths per year in…
-
Methodological aspects of the interpretation of non-invasive biomarkers of liver fibrosis: a 2008 update. Key publication Review
This review summarizes the methodological aspects of the interpretation of non-invasive…
-
Comparison of liver stiffness, fibrotest and liver biopsy for assessment of liver fibrosis in kidney-transplant patients with chronic viral hepatitis.
To assess the accuracy of the noninvasive tools, fibrotest (FT) and liver…
-
Comparison of non-invasive liver fibrosis biomarkers in HIV/HCV co-infected patients: the fibrovic study--ANRS HC02.
### Background/Aims To compare non-invasive biological liver fibrosis scores, as alternatives…
-
Is it possible to predict HCV-related liver cirrhosis non-invasively through routine laboratory parameters? Review
It is estimated that hepatitis C virus (HCV) infects chronically about 160…
-
Role of leisure-time physical activity in nonalcoholic fatty liver disease: a population-based study.
### Unlabelled Physical activity (PA) is commonly recommended for nonalchoholic fatty liver disease…
-
Longitudinal assessment of hepatitis C fibrosis progression by collagen and smooth muscle actin morphometry in comparison to serum markers.
### Background Assessment of fibrosis progression in chronic liver disease relies upon non…
-
Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients.
### Objective Liver biopsy, the gold standard for assessing hepatitis C virus (HCV…
-
Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. Key publication
### Background Liver biopsy is considered as the gold standard for assessing non…
-
Biochemical markers of liver fibrosis: a comparison with historical features in patients with chronic hepatitis C.
### Objectives Liver fibrosis in chronic hepatitis C is related to sex, age…
-
Diagnostic performance of a new noninvasive test for nonalcoholic steatohepatitis using a simplified histological reference. Key publication
### Background One of the unmet needs in patients with metabolic risks is…
-
Biochemical and biophysical assessment of MTX-induced liver fibrosis in psoriasis patients: Fibrotest predicts the presence and Fibroscan predicts the absence of significant liver fibrosis.
### Background Methotrexate (MTX) use is associated with hepatic fibrosis in psoriasis patients…
-
Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C.
### Background And Aims Transient elastography (FibroScan; Echosens, Paris, France) is a novel…
-
The diagnostic performance of a simplified blood test (SteatoTest-2) for the prediction of liver steatosis. Key publication
### Background Serum biomarkers of steatosis such as the SteatoTest are recommended for…
-
An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (FibroTest-ActiTest) and viral load. Key publication
### Background The combination of transaminases (ALT), biopsy, HBeAg and viral load have…
-
A brief review on molecular, genetic and imaging techniques for HCV fibrosis evaluation. Review
### Background Chronic HCV is one of the major causes of morbidity and…
-
Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus.
Fibromax is a diagnostic tool composed of the combination of 4 non…
-
Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review.
### Background Many blood tests have been proposed as alternatives to liver biopsy…
-
Diagnostic accuracy of the fibrotest in hemodialysis and renal transplant patients with chronic hepatitis C virus.
### Background An accurate diagnosis of hepatitis C virus (HCV)-related liver lesions…
-
Transient elastography and other noninvasive tests to assess hepatic fibrosis in patients with viral hepatitis. Review
The limitations of liver biopsy (invasive procedure, sampling errors, inter-observer variability…
-
HCV-GenoFibrotest: a combination of viral, liver and genomic (IL28b, ITPA, UGT1A1) biomarkers for predicting treatment response in patients with chronic hepatitis C.
### Background And Aim Three gene polymorphisms, interferon-lambda-3 (IL28B), inosinetriphosphatase (ITPA…
-
The accuracy of the FIB-4 index for the diagnosis of mild fibrosis in chronic hepatitis B.
### Background The Fib-4 index is a simple and inexpensive biomarker to…
-
Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics.
We applied our 'clinical glycomics' technology, based on DNA sequencer/fragment analyzers…
-
A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease.
BACKGROUND: Biochemical markers for liver fibrosis (FibroTest) and necroinflammatory features (ActiTest) are…
-
Variability of the area under the receiver operating characteristic curves in the diagnostic evaluation of liver fibrosis markers: impact of biopsy length and fragmentation.
### Background The area under the receiver operating characteristic (ROC) curve is widely…
-
Biomarkers for liver disease in urea cycle disorders.
…at risk for this complication. ### Trial Registration This study has been registered…
-
Impact of steatosis and inflammation definitions on the performance of NASH tests.
### Background And Aim One of the unmet needs in subjects with metabolic…
-
Interferon-γ-inducible protein-10 in chronic hepatitis C: Correlations with insulin resistance, histological features & sustained virological response.
### Background & Objectives One of the multiple factors contributing to virological response in…
-
Progression of liver fibrosis among injection drug users with chronic hepatitis C.
Although most hepatitis C virus (HCV) infections are acquired by injection drug…
-
Serum bile acid levels as a predictor for the severity of liver fibrosis in patients with chronic hepatitis C.
Serum bile acids (SBAs) are commonly elevated in cholestatic liver diseases, but…
-
Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosis.
### Background & Aims Patients with chronic hepatitis C virus infection and advanced fibrosis…
-
Evaluation of FibroTest-ActiTest in children with chronic hepatitis C virus infection. Key publication
FibroTest-ActiTest (FT-AT) has been validated in adults with chronic hepatitis…
-
A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. Key publication
### Background FibroTest, a noninvasive method of measuring biomarkers of liver fibrosis, is…
-
Validation of biochemical markers for the prediction of liver fibrosis and necroinflammatory activity in hemodialysis patients with chronic hepatitis C.
### Background Liver biopsy is an imperfect gold standard for assessing the disease…
-
The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis.
### Background & Aim Fibrosis is an independent predictor of death in nonalcoholic steatohepatitis…
-
Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C.
### Background/Aims In chronic hepatitis C, biopsy is the gold standard for…
-
Biochemical markers of fibrosis in patients with chronic hepatitis C: a comparison with prothrombin time, platelet count, and age-platelet index.
As an alternative to liver biopsy, an index of five biochemical markers…
-
Noninvasive procedures to evaluate liver involvement in HIV-1 vertically infected children.
### Objectives : Progressive liver injury is a concern in HIV-infected children exposed…
-
Proficiency of transient elastography compared to liver biopsy for the assessment of fibrosis in HIV/HBV-coinfected patients.
Transient elastography (TE) is a noninvasive technique to evaluate liver fibrosis. We…
-
Three Neglected STARD Criteria Reduce the Uncertainty of the Liver Fibrosis Biomarker FibroTest-T2D in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Key publication
**Background/Objectives:** Bariatric surgery (BS), drugs approved for type-2-diabetes (T2D…
-
Coffee consumption and nonalcoholic fatty liver onset: a prospective study in the general population.
Retrospective studies suggest that coffee consumption may exert beneficial effects in patients…
-
Hepatitis C virus viremia and low platelet count: a study in a hepatitis B & C endemic area in Taiwan.
### Background & Aims Hepatitis C virus (HCV) infection has been shown to be…
-
Validation of noninvasive biomarkers (FibroTest, SteatoTest, and NashTest) for prediction of liver injury in patients with morbid obesity.
### Background Liver biopsy is considered as the gold standard for assessing nonalcoholic…
-
Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases.
Liver stiffness was measured by transient elastography (FibroScan) in 228 consecutive patients…
-
Optimal correlation between different instruments for Fibrotest-Actitest protein measurement in patients with chronic hepatitis C.
### Objectives Combination of alpha 2-macroglobulin, haptoglobin, apolipoprotein-A1, gamma-glutamyl transpeptidase…
-
FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy. Meta Analysis
### Background The accurate diagnosis of hepatitis C virus (HCV)-related fibrosis is…
-
Real-world efficacy and safety of ombitasvir, paritaprevir/r+dasabuvir+ribavirin in genotype 1b patients with hepatitis C virus cirrhosis.
### Background Direct antiviral agents (DAA) showed very good results in terms of…
-
Noninvasive methods, including transient elastography, for the detection of liver disease in adults with cystic fibrosis.
### Background Liver disease is the third leading cause of mortality in patients…
-
Relationship between the Fibrotest and portal hypertension in patients with liver disease.
### Background The best technique to estimate portal hypertension (PHT) is to measure…
-
FibroMAX: towards a new universal biomarker of liver disease? Review
Among the noninvasive alternatives to liver biopsy, several studies have demonstrated the…
-
Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. Key publication
### Background The FibroTest and ActiTest are noninvasive biochemical markers of liver injury…
-
Impact of quality control accepted inter-laboratory variations on calculated Fibrotest/Actitest scores for the non-invasive biochemical assessment of liver fibrosis.
### Introduction Non-invasive, i.e. serum-based assessment of liver fibrosis is…
-
[Results transferability on RXL, ARX, X-Pand, BN2 (Dade Behring) and modular DP (Roche Diagnostics) analysers: application to component assays of fibrotest and Actitest].
The follow up of patients with chronic liver diseases and the data…
-
Comparison of transient elastography (FibroScan), FibroTest, APRI and two algorithms combining these non-invasive tests for liver fibrosis staging in HIV/HCV coinfected patients: ANRS CO13 HEPAVIH and FIBROSTIC collaboration.
### Objectives Combining noninvasive tests increases diagnostic accuracy for staging liver fibrosis in…
-
Transient elastography and biomarkers for liver fibrosis assessment and follow-up of inactive hepatitis B carriers.
### Background Non invasive methods for fibrosis evaluation remain to be validated longitudinally…
-
Coffee and Caffeine Are Associated With Decreased Risk of Advanced Hepatic Fibrosis Among Patients With Hepatitis C.
### Background & Aims Coffee or caffeine has been proposed to protect against hepatic…
-
Noninvasive Assessment of Liver Fibrosis. Key publication Review
-
Diagnostic value of serum protein profiling by SELDI-TOF ProteinChip compared with a biochemical marker, FibroTest, for the diagnosis of advanced fibrosis in patients with chronic hepatitis C.
### Background FibroTest has been validated for the diagnosis of liver fibrosis in…
-
Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: proof of concept and first application in a large population.
### Background & Aims Time-dependent statistics have been used to assess liver fibrosis…
-
Early detection in routine clinical practice of cirrhosis and oesophageal varices in chronic hepatitis C: comparison of transient elastography (FibroScan) with standard laboratory tests and non-invasive scores.
### Background/Aims To assess prospectively the accuracy of transient elastography (TE, FibroScan…
-
The diagnostic value of combining carbohydrate-deficient transferrin, fibrosis, and steatosis biomarkers for the prediction of excessive alcohol consumption.
### Background And Aim The validity of biomarkers of excessive alcohol drinking (EAD…
-
Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19. Key publication
In patients with non-alcoholic fatty liver disease (NAFLD) with or without…
-
The Diagnostic Value of FibroTest and Hepascore as Non-Invasive Markers of Liver Fibrosis in Primary Sclerosing Cholangitis (PSC).
The aim of this study was to evaluate the diagnostic usefulness of…
-
Higher serum testosterone is associated with increased risk of advanced hepatitis C-related liver disease in males.
### Unlabelled Males have strikingly increased risk of advanced liver disease. However, the…
-
Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference. Key publication
### Background Blood tests of liver injury are less well validated in non…
-
Assessment of liver fibrosis: noninvasive means.
Liver biopsy, owing to its limitations and risks, is an imperfect gold…
-
Racial differences in the association between adiposity measures and the risk of hepatitis C-related liver disease.
### Background African Americans have lower reported likelihood of hepatitis C virus-related…
-
Liver fibrosis regression and progression during controlled hepatitis B virus infection among HIV-HBV patients treated with tenofovir disoproxil fumarate in France: a prospective cohort study.
### Introduction Long-term tenofovir disoproxil fumarate (TDF) use has been associated with…
-
Non-invasive diagnostic assessment tools for the detection of liver fibrosis in patients with suspected alcohol-related liver disease: a systematic review and economic evaluation.
### Background Excessive alcohol consumption may lead to the development of alcohol-related…
-
EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. Key publication
-
Clinical and genetic definition of serum bilirubin levels for the diagnosis of Gilbert syndrome and hypobilirubinemia.
Mostrando la lista completa de resultados. La página se renderiza en el servidor y no está paginada.